Cambridge-based Biogen will stop developing its controversial Alzheimer's drug

Biogen will stop developing its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster before stumbling soon after its launch a couple years ago.

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Japan ,Japanese , ,Drug Administration ,Biogen Inc ,Massachusetts Based Biogen ,Alzheimers Disease ,Biogen ,Alzheimers Treatment ,Food And Drug Administration ,Blockbuster Drug ,